Products
Albutrepenonacog Alfa Biosimilar Fusion Protein (Factor IX) for Research
Pre-Made Albutrepenonacog Alfa Biosimilar, Fusion Protein targeting F9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Albutrepenonacog alfa (rIX-RFP) is a recombinant fusion protein that links a recombinant coagulation factor IX (rFIX) with a recombinant human albumin (rAlbumin). Patients with haemophilia B lack factor IX, a protein needed for normal clotting of the blood, and as a result, they bleed readily. The albutrepenonacog alfa, works in the body in the same way as human factor IX and replaces the missing factor IX, thereby helping the blood to clot and giving temporary control of bleeding.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-726-1mg | 1mg | 3090 |
| GMP-Bios-INN-726-10mg | 10mg | |
| GMP-Bios-INN-726-100mg | 100mg | |
| GMP-Bios-INN-726-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Albutrepenonacog Alfa Biosimilar, Fusion Protein targeting F9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 |
| INN Name | Albutrepenonacog Alfa |
| Target | F9 |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - F9 (coagulation factor 9, coagulation factor IX) recombinant - ALB (albumin, human serum albumin, HSA) 25-609 |
| VD LC | Fusion - F9 (coagulation factor 9, coagulation factor IX) recombinant - ALB (albumin, human serum albumin, HSA) 25-609 |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | CSL Behring (King of Prussia PA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - F9
1. Protein Coagulation factor IX
2. Gene F9
3. Organism Homo sapiens (Human)
Function
Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa.
Miscellaneous
In 1952, one of the earliest researchers of the disease, Dr. R.G. Macfarlane used the patient's surname, Christmas, to refer to the disease and also to refer to the clotting factor which he called the 'Christmas Factor' At the time Stephen Christmas was a 5-year-old boy. He died in 1993 at the age of 46 from acquired immunodeficiency syndrome contracted through treatment with blood products.
Catalytic activity
Selective cleavage of Arg-|-Ile bond in factor X to form factor Xa.
